XEN45 Gelstent Implantation in the Treatment of Glaucoma Secondary to Fuchs Uveitis Syndrome

References

• Fuchs E Ueber komplikationen der heterochromie. Published online 1906.
   Google Scholar
• La Hey E, De Vries J, Langerhorst CT, Baarsma GS, Kijlstra A. Treatment and prognosis of secondary glaucoma in Fuchs’ heterochromic iridocyclitis. Am J Ophthalmol. 1993;116(3):327–340. doi:10.1016/s0002-9394(14)71350-9.
   PubMed Web of Science ®Google Scholar
• Voykov B, Deuter C, Zierhut M, et al. Is cyclophotocoagulation an option in the management of glaucoma secondary to Fuchs’ uveitis syndrome? Graefes Arch Clin Exp Ophthalmol. 2014;252(3):485–489.doi:10.1007/s00417-013-2558-2.
   PubMed Web of Science ®Google Scholar
• Jones NP. Glaucoma in Fuchs’ heterochromic uveitis: aetiology, management and outcome. Eye. 1991;5(6):662–667. doi:10.1038/eye.1991.122.
   PubMedGoogle Scholar
• Sun Y, Ji Y. A literature review on Fuchs uveitis syndrome: an update. Surv Ophthalmol. 2020;65(2):133–143. doi:10.1016/j.survophthal.2019.10.003.
   PubMed Web of Science ®Google Scholar
• Bettis DI, Morshedi RG, Chaya C, Goldsmith J, Crandall A, Zabriskie N. Trabeculectomy With Mitomycin C or Ahmed Valve Implantation in Eyes With Uveitic Glaucoma. J Glaucoma. 2015;24(8):591–599. doi:10.1097/IJG.0000000000000195.
   PubMed Web of Science ®Google Scholar
• Esfandiari H, Loewen NA, Hassanpour K, et al. Fuchs heterochromic iridocyclitis-associated glaucoma: a retrospective comparison of primary Ahmed glaucoma valve implantation and trabeculectomy with mitomycin C. F1000Res. 2018;7:876. doi:10.12688/f1000research.15244.2.
   PubMedGoogle Scholar
• Nilforushan N, Yadgari M, Alemzadeh SA. Surgical management of glaucoma in Fuchs uveitis syndrome: trabeculectomy or Ahmed glaucoma valve. J Curr Ophthalmol. 2019;31(1):24–30. doi:10.1016/j.joco.2018.10.005.
   PubMed Web of Science ®Google Scholar
• Voykov B, Doycheva D, Deuter C, Leitritz MA, Dimopoulos S, William A. Outcomes of Ahmed Glaucoma valve implantation for Glaucoma Secondary to Fuchs Uveitis Syndrome. Ocul Immunol Inflamm. 2017;25(6):760–766. doi:10.3109/09273948.2016.1168454.
   PubMed Web of Science ®Google Scholar
• You Y-A, Wu Y, Hu S. Surgical management of secondary glaucoma in Fuchs’ heterochromic iridocyclitis. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1785–1790. doi:10.1007/s00417-013-2312-9.
   PubMed Web of Science ®Google Scholar
• Buffault J, Graber M, Bensmail D, et al. Efficacy and safety at 6 months of the XEN implant for the management of open angle glaucoma. Sci Rep. 2020;10. doi:10.1038/s41598-020-61319-1.
   PubMed Web of Science ®Google Scholar
• De Gregorio A, Pedrotti E, Stevan G, Bertoncello A, Morselli S. XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice. Clin Ophthalmol. 2018;12:773–782. doi:10.2147/OPTH.S146919.
   PubMed Web of Science ®Google Scholar
• Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: a systematic review and meta-analysis. PLoS ONE. 2017;12(8):e0183142. doi:10.1371/journal.pone.0183142.
   PubMed Web of Science ®Google Scholar
• Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Efficacy, safety, and risk factors for failure of standalone Ab Interno gelatin microstent implantation versus standalone trabeculectomy. Ophthalmology. 2017;124(11):1579–1588.doi:10.1016/j.ophtha.2017.05.004.
   PubMed Web of Science ®Google Scholar
• Widder RA, Dietlein TS, Dinslage S, Kühnrich P, Rennings C, Rössler G. The XEN45 Gel Stent as a minimally invasive procedure in glaucoma surgery: success rates, risk profile, and rates of re-surgery after 261 surgeries. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):765–771. doi:10.1007/s00417-018-3899-7.
   PubMed Web of Science ®Google Scholar
• Shaarawy TM, Grehn F, Sherwood M, eds. WGA guidelines on design and reporting of glaucoma surgical trials. The Hague:Kugler Publications; 2009. https://rds-tue.ibs-bw.de/link?kid=1654926744
   Google Scholar
• Mohamed Q, Zamir E. Update on Fuchs’ uveitis syndrome. Curr Opin Ophthalmol. 2005;16(6):356–363. doi:10.1097/01.icu.0000187056.29563.8d.
   PubMedGoogle Scholar
• William A, Spitzer MS, Doycheva D, Dimopoulos S, Leitritz MA, Voykov B. Comparison of ab externo trabeculotomy in primary open-angle glaucoma and uveitic glaucoma: long-term outcomes. Clin Ophthalmol. 2016;10:929–934. doi:10.2147/OPTH.S102414.
   PubMed Web of Science ®Google Scholar
• Towler HMA, McCluskey P, Shaer B, Lightman S. Long-term follow-up of trabeculectomy with intraoperative 5-fluorouracil for uveitis-related glaucoma. Ophthalmology. 2000;107(10):1822–1828. doi:10.1016/S0161-6420(00)00351-1.
   PubMed Web of Science ®Google Scholar
• Walkden A, Mercieca K, Perumal D, Anand N. Primary glaucoma surgery in Fuchs’ heterochromic uveitis: a comparison of trabeculectomy versus deep sclerectomy. Ther Adv Ophthalmol. 2019;11:2515841419869761. doi:10.1177/2515841419869761.
   Web of Science ®Google Scholar
• Towler HMA, Bates AK, Broadway DC, Lightman S. Primary trabeculectomy with 5-fluorouracil for glaucoma secondary to uveitis. Ocul Immunol Inflamm. 1995;3(3):163–170. doi:10.3109/09273949509069109.
   PubMedGoogle Scholar
• Mursch-Edlmayr AS, Mojon DS, Ring M, Laubichler P, Luft N, Priglinger SG. Comparison of deep sclerokeratodissection, a new variant of nonpenetrating glaucoma surgery, with deep sclerectomy. Indian J Ophthalmol. 2016;64(12):914–918. doi:10.4103/0301-4738.198863.
   PubMed Web of Science ®Google Scholar
• Sng CC, Wang J, Hau S, Htoon HM, Barton K. XEN-45 collagen implant for the treatment of uveitic glaucoma. Clin Exp Ophthalmol. 2018;46(4):339–345. doi:10.1111/ceo.13087.
   PubMed Web of Science ®Google Scholar
• Qureshi A, Jones NP, Au L. Urgent management of secondary Glaucoma in Uveitis using the Xen-45 Gel Stent. J Glaucoma. 2019;28(12):1061–1066. doi:10.1097/IJG.0000000000001389.
   PubMed Web of Science ®Google Scholar
• Rauchegger T, Angermann R, Willeit P, Schmid E, Teuchner B. Two-year outcomes of minimally invasive XEN Gel Stent implantation in primary open-angle and pseudoexfoliation glaucoma. Acta Ophthalmol. 2020 Sept 30. Published online. doi:10.1111/aos.14627.
   Web of Science ®Google Scholar
• Gillmann K, Bravetti GE, Rao HL, Mermoud A, Mansouri K. Combined and stand-alone XEN 45 gel stent implantation: 3-year outcomes and success predictors. Acta Ophthalmol. 2020 September 15. Published online. doi:10.1111/aos.14605.
   PubMed Web of Science ®Google Scholar
• Amsler M, Verrey F. Hétérochromie de Fuchs et fragilité vasculaire. OPH. 1946;111(2–3):177–181. doi:10.1159/000300320.
   Google Scholar
• Galal A, Bilgic A, Eltanamly R, Osman A. XEN Glaucoma implant with Mitomycin C 1-year follow-up: result and complications. J Ophthalmol. 2017;2017:5457246. doi:10.1155/2017/5457246.
   PubMed Web of Science ®Google Scholar
• Gillmann K, Bravetti GE, Mermoud A, Rao HL, Mansouri K. XEN Gel Stent in Pseudoexfoliative Glaucoma: 2-year results of a prospective evaluation. J Glaucoma. 2019;28(8):676–684. doi:10.1097/IJG.0000000000001295.
   PubMed Web of Science ®Google Scholar
• Busch T, Skiljic D, Rudolph T, Bergström A, Zetterberg M. Learning curve and one-year outcome of XEN 45 gel stent implantation in a swedish population. Clin Ophthalmol. 2020;14:3719–3733. doi:10.2147/OPTH.S267010.
   PubMed Web of Science ®Google Scholar
• Mansouri K, Guidotti J, Rao HL, et al. Prospective evaluation of standalone XEN gel implant and combined phacoemulsification-XEN Gel implant surgery: 1-year results. JGlaucoma. 2018;27(2):140–147.doi:10.1097/IJG.0000000000000858.
   PubMed Web of Science ®Google Scholar
• Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010;117(7):1324–1330.doi:10.1016/j.ophtha.2009.11.038.
   PubMed Web of Science ®Google Scholar
• Jones NP. Fuchs’ heterochromic uveitis: an update. Surv Ophthalmol. 1993;37(4):253–272. doi:10.1016/0039-6257(93)90009-V.
   PubMed Web of Science ®Google Scholar
• Daas L, Seitz B, Pleyer U. [Fuchs uveitis]. Ophthalmologe. 2017;114(5):481–492. doi:10.1007/s00347-017-0494-y.
   PubMed Web of Science ®Google Scholar
• Bauer D, Kasper M, Walscheid K, et al. Alteration of MCP-1 and MMP-9 in aqueous humor is associated with secondary glaucoma in fuchs uveitis syndrome. Ocul Immunol Inflamm. 2020;28(4):688–698.doi:10.1080/09273948.2019.1609049.
   PubMed Web of Science ®Google Scholar
• Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β*. Ann Rev Immunol. 1998 April 1;16(1):137–161. Published online. doi:10.1146/annurev.immunol.16.1.137.
   PubMedGoogle Scholar
• Pfeiffer N, Voykov B, Renieri G, et al. First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery. PLoS One. 2017;12(11):e0188899.doi:10.1371/journal.pone.0188899.
   PubMed Web of Science ®Google Scholar